 Receptors, Progesterone
"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
| Descriptor ID |
D011980
|
| MeSH Number(s) |
D12.776.260.698.750.765 D12.776.826.750.765 D12.776.930.669.750.765
|
| Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Receptors, Progestin
- Progesterone Receptors
- Progestin Receptors
- Progesterone Receptor
- Receptor, Progesterone
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- DNA-Binding Proteins [D12.776.260]
- Receptors, Cytoplasmic and Nuclear [D12.776.260.698]
- Receptors, Steroid [D12.776.260.698.750]
- Receptors, Progesterone [D12.776.260.698.750.765]
- Receptors, Cytoplasmic and Nuclear [D12.776.826]
- Receptors, Steroid [D12.776.826.750]
- Receptors, Progesterone [D12.776.826.750.765]
- Transcription Factors [D12.776.930]
- Receptors, Cytoplasmic and Nuclear [D12.776.930.669]
- Receptors, Steroid [D12.776.930.669.750]
- Receptors, Progesterone [D12.776.930.669.750.765]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 1 | 4 | | 1984 | 0 | 1 | 1 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 0 | 1 | | 1987 | 3 | 1 | 4 | | 1988 | 10 | 1 | 11 | | 1989 | 6 | 1 | 7 | | 1990 | 2 | 0 | 2 | | 1991 | 6 | 1 | 7 | | 1992 | 4 | 3 | 7 | | 1993 | 1 | 0 | 1 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 2 | 3 | | 2002 | 0 | 3 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 3 | 5 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 2 | 4 | 6 | | 2011 | 1 | 4 | 5 | | 2012 | 0 | 6 | 6 | | 2013 | 1 | 5 | 6 | | 2014 | 4 | 4 | 8 | | 2015 | 2 | 4 | 6 | | 2016 | 3 | 5 | 8 | | 2017 | 2 | 5 | 7 | | 2018 | 2 | 5 | 7 | | 2019 | 4 | 3 | 7 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Mascia F, Mazo I, Alterovitz WL, Karagiannis K, Wu WW, Shen RF, Beaver JA, Rao VA. In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
-
Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
-
Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, Ito Y, Ueno T, Ohno S, Nakamura Y, Takahashi S. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(2):331-341.
-
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
-
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
-
Kantor O, Barrera E, Kopkash K, Pesce C, Barrera E, Winchester DJ, Yao K. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.
-
Omar M, Laknaur A, Al-Hendy A, Yang Q. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. BMC Womens Health. 2019 07 09; 19(1):92.
-
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98.
-
Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. J Clin Oncol. 2019 04 10; 37(11):862-866.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|